Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: Evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity

Blood

Volumn 113, Issue 13, 2009, Pages 3119-3129

  Pende, Daniela ^a   Marcenaro, Stefania ^b   Falco, Michela ^c   Martini, Stefania ^a   Bernardo, Maria Ester ^d,e   Montagna, Daniela ^d,e   Romeo, Elisa ^c   Cognet, Celine ^f   Martinetti, Miryam ^g   Maccario, Rita ^g   Mingari, Maria Cristina ^a,b   Vivier, Eric ^f   Moretta, Lorenzo ^a,b,c   Locatelli, Franco ^d   Moretta, Alessandro ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; MONOCLONAL ANTIBODY; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; ALLOIMMUNITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING ASSAY; BLAST CELL; CELL ACTIVITY; CELL CLONING; CELL ISOLATION; CELL KILLING; CHILD; CHILD HEALTH CARE; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR SELECTION; FEMALE; FUNCTIONAL ASSESSMENT; GENOTYPE; GRAFT FAILURE; GRAFT RECIPIENT; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA; LEUKEMIA CELL; MALE; NATURAL KILLER CELL; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; SCHOOL CHILD; TARGET CELL;

EID: 63849104548     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-164103     Document Type: Article

References (43)

1. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science.2002;295:2097-2100.
2. Velardi A, Ruggeri L, Moretta A, Moretta L. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol. 2002;23:438-444.
3. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110:433-440.
4. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217-251.
5. Moretta A, Bottino C, Vitale M, et al. Receptors for HLA-class I molecules in human natural killer cells. Annu Rev Immunol. 1996;14:619-648.
6. Lanier LL. NK cell receptors. Annu Rev Immunol. 1998;16:359-393.
7. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol. 1999;17:875-904.
8. Long EO. Signal sequences stop killer cells. Nature. 1998;391:740-743.
9. Moretta A, Sivori S, Vitale M, et al. Existence of both inhibitory(p58) and activatory(p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med. 1995;182:875-884.
10. Stewart CA, Laugier-Anfossi F, Vely F, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005;102:13224-13229.
11. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795-799.
12. Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7:753-763.
13. Valiante NM, Uhrberg M, Shilling HG, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7:739-751.
14. Draghi M, Yawata N, Gleimer M, Yawata M, Valiante NM, Parham P. Single-cell analysis of the human NK cell response to missing self and its inhibition by HLAclass I. Blood. 2005;105: 2028-2035. 15. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. Asubset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood. 2005;105:4416-4423.
15. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436:709-713.
16. Anfossi N, André P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25:331-342.
17. Ljunggren H-G, Karre K. In search of the "missing self". MHC molecules and NK cell recognition. Immunol Today. 1990;11:237-244.
18. Leung W, Iyengar R, Turner V, et al. Determinant of anti-leukemia effects of allogeneic NK cells. J Immunol. 2004;172:644-650.
19. Leung W, Iyengar R, Triplett B, et al. Comparison of killer Ig-like receptor genotyping and phenotyp-ing for selection of allogeneic blood stem cell donors. J Immunol. 2005;174:6540-6545.
20. Pende D, Spaggiari GM, Marcenaro S, et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the poliovirus receptor(CD155) and nectin-2(CD112). Blood. 2005;105: 2066-2073.
21. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
22. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by bone marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98:461-466.
23. Gerna G, Revello MG, Percivalle E, Torsellini M. A 6-h microneutralization assay for human cyto-megalovirus antibody by using monoclonal antibodies. Serodiagn Immunother Infect Dis. 1990; 4:243-247.
24. Scheltinga SA, Johnston-Dow LA, White CB, et al. Ageneric sequencing based typing approach for the identification of HLA-Adiversity. Hum Immunol. 1997;57:120-128.
25. van der Vlies SA, Voorter CEM, Van Den Berg-Loonen EM. A reliable and efficient high resolution typing method for HLA-C using sequence-based typing. Tissue Antigens. 1998;52: 558-568.
26. Voorter CEM, Rozemuller EH, De Bruyn-Geraets D, et al. Comparison of DRB sequence-based typing using different strategies. Tissue Antigens. 1997;49:471-476.
27. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA system, 1998. Tissue Antigens. 1999;53:407-446.
28. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223.
29. Bottino C, Castriconi R, Pende D, et al. Identification of PVR(CD155) and nectin-2(CD112) as ce surface ligands for the human DNAM-1(CD226) activating molecule. J Exp Med. 2003;198:557-567.
30. Pende D, Parolini S, Pessino A, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cyto-toxixity mediated by human natural killer cells. J Exp Med. 1999;190:1505-1516.
31. Biassoni R, Falco M, Cambiaggi A, et al. Amino acid substitutions can influence the natural killer(NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by "group 2" or "group 1" NK clones. J Exp Med. 1995;182:605-609.
32. Zambello R, Falco M, Della Chiesa M, et al. Expression and function of KIR and natural cytotox-icity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood. 2003;102 1797-1805.
33. O'Connor GM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol. 2007;178:235-241.
34. TrundleyA, Frebel H, Jones D, Chang C, Trowsdale J. Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies. Eur J Immunol. 2007;37:780-787.
35. Vitale M, Carlomagno S, Falco M, et al. Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2. Int Immunol. 2004;16:1459-1466.
36. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7:329-339.
37. Foley B, De Santis D, Lathbury L, Christiansen F, Witt C. KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-nega-tive individuals. Int Immunol. 2008;20:555-563.
38. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol. 2007;179:854-868.
39. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol. 2008;180:3969-3979.
40. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004;23:255-259.
41. Moretta A, Vitale M, Bottino C, et al. P58 molecules as putative receptors for major histocom-patibility complex(MHC) class I molecules in human natural killer(NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med. 1993;178:597-604.
42. Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1-and NK2-specific natural killer cells. Proc Natl Acad Sci U S A. 1993;90:12000-12004.
43. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333-339.